Brain Disease Modalities and Software Market - A Global and Regional Analysis: Focus on Product, Indication, Patient Type, End User, and Regional Analysis - Analysis and Forecast, 2022-2031
Market Report Coverage - Brain Disease Modalities and Software
Market Segmentation
- Indication - Brain Diseases (Brain and Central Nervous System Cancer, Idiopathic Epilepsy, Ischemic stroke, and Other Brain Diseases) and Neurodegenerative Diseases (Alzheimer’s Disease, Multiple Sclerosis, Parkinson’s Disease, Motor Neuron Disease, and Other Neurodegenerative Diseases)
- Patient Type - Adults and Paediatrics and Infants
- End User - Hospitals and Clinics, Ambulatory Surgery Centers, and Diagnostic Imaging Centers
- Product Type - Brain Imaging Modalities (PET Devices, CT Devices, MRI Devices, PET-CT, and PET-MRI) and Brain Analysis Software
- North America - U.S. and Canada
- Europe - Germany, U.K., Spain, Italy, France, and Rest-of-Europe
- Asia-Pacific - Japan, China, South Korea, India, Australia and New Zealand, and Rest-of-Asia-Pacific
- Rest-of-the-World - Latin America and Middle East and Africa
- Increasing Prevalence of Neurological Disorders
- Rising AI Integration in the Field of Medical Imaging
- Increasing Demand for Safer and Non-Invasive Devices for Medical Imaging
- High Upfront Cost of Imaging Devices
- Declining Availability of Helium
- Integration of Imaging Solutions with Novel Biomarkers to Enable Diagnosis of a Wider Range of Neurological Disorders
- Integration of 3D Amplified MRI, a New Technological Advancement
United Imaging Healthcare Co., Ltd., Koninklijke Philips N.V., General Electric Company, Canon, Inc., Siemens Healthineers AG, Vuno Co., Ltd., Fujifilm Holdings Corporation, Aspect Imaging, IXICO, QMENTA, Cortechs.ai, Quantib, Brainomix, Qure.AI, Imaging Biometrics, LLC, A.I. Analysis, Inc.
How This Report Can Add Value
Assuming that the reader is a developer of brain disease modalities and software, they will be able to do the following:
- Understand their position as compared to some of the key players in the market
- Stay updated with novel technology integration, features, and the latest developments in the market
- Understand the impact of COVID-19 on the adoption of brain disease modalities and software and the entry barriers as a result of it
- Gain insights into which regions to target globally based on factors such as the amount of technology integration in medical imaging and the quality of access to affordable medical imaging
- Gain insights into the end user perception with respect to the adoption of imaging modalities and software
- Identify some of the key players in the market and understand their valuable contribution
- How has COVID-19 impacted the adoption of brain imaging modalities and software?
- What are the key regulations governing the brain disease modalities and software market in key regions?
- Which technological developments are projected to have the maximum influence on the global brain disease modalities and software market?
- Who are the leading players holding significant dominance in the global brain disease modalities and software market currently?
- What are the drivers and restraints for the global brain disease modalities and software market?
- Which region has the highest growth rate in the global brain disease modalities and software market?
- Who are the emerging companies in the global brain disease modalities and software market?
Brain imaging modalities include conventional modalities such as MRI and CT scans and the more emerging imaging technologies such as PET and combined functionalities of PET with MRI or CT. While MRI is a conventional technology due to its age-long usage, various advanced MRI techniques such as diffusion tensor imaging (DTI), diffusion-weighted imaging (DWI), susceptibility-weighted imaging (SWI), and dynamic susceptibility contrast (DSC) imaging are being employed more widely in regions such as North America and Europe.
Brain imaging software offers a valuable addition to the scanned images obtained through these modalities with respect to quantitative analysis. Quantitative insights into the structure, biomarkers, and other subtle abnormalities in the brain are a valuable tool in aiding in a more accurate diagnosis of neurological disorders.
The global brain disease modalities and software market report highlights that the market was valued at $13,055.7 million in 2021 and is expected to reach $21,867.6 million by the end of 2031. The market is expected to grow at a CAGR of 5.31% during the forecast period from 2022 to 2031.
Global Brain Disease Modalities and Software Market Drivers
The market is driven by factors such as the increasing prevalence of neurological disorders, the rising AI integration in the field of medical imaging, and the increasing demand for safer and non-invasive devices for medical imaging.
There has been a paradigm shift in patient preference from invasive to minimally invasive modes of diagnosis as well as treatment. MRI, CT, and PET-CT scans are popular non-invasive methods of medical imaging that produce three-dimensional images of the body to aid in the diagnosis of diseases. Furthermore, there is also a rising preference for safer imaging technologies that employ minimal radiation.
Global Brain Disease Modalities and Software Market Challenges
The factors restraining market growth include the high upfront cost of imaging devices and the declining availability of helium. Hardware devices for medical imaging, such as MRI, CT, and PET-CT scanners, are capital-intensive equipment with a high upfront cost. Lack of affordability is a major factor restraining the growth of the market in emerging economies such as Latin America and Middle East and Africa. Due to the expensive nature of these imaging modalities, there is a considerable lack of accessibility across the population. As a result, the low- and middle-income population usually relies on alternative clinical tests such as blood biomarker tests and cognitive scoring tests as a preliminary method to diagnose neurological disorders.
Furthermore, the shortage of helium globally particularly affects the field of medical imaging in the healthcare sector. MRI scanners require a sufficient quantity of liquid helium, below which the functioning of the scanner is compromised. Therefore, challenges faced by manufacturers of medical imaging modalities associated with the procurement of supercooled liquid helium have a direct effect on the smooth functioning of the machine, thereby hindering the growth of the market.
Global Brain Disease Modalities and Software Market Opportunities
The opportunity for growth of the global brain disease modalities and software market lies in the integration of imaging solutions with novel biomarkers to enable diagnosis of a wider range of neurological disorders and integration of 3D amplified MRI, a new technological advancement in the field of brain imaging.
This new development, i.e., 3D amplified MRI, enables physicians to view pulsations of the brain as opposed to a conventional static MRI image. The real-time visualization of brain movement holds significant potential to detect hard-to-find abnormalities, thereby aiding in the diagnosis process. Companies in the global brain disease modalities and software market can leverage this new technological advancement to gain a competitive edge in the market.
Impact of COVID-19 on the Global Brain Disease Modalities and Software MarketThere was a decline in the demand for neuroimaging services as it was offset by the demand for respiratory imaging and tests for COVID-19 treatment. The need to fulfill the demand for critical supplies for COVID-19 management, such as pulse oximeters, ventilators, and oxygen concentrators, overshadowed the demand and supply of the neuroimaging modalities. Although the neuroimaging market is experiencing overall growth, most of the hospitals have reallocated their budget to stock the resources required to fight COVID-19 as they appear to be more crucial.
The COVID-19 pandemic led to government-mandated travel restrictions, especially during the peak phases, leading to a shifting preference among the global population from physical visits to home-based care. This has led to a further push in demand for wearable imaging scanners that can be used at home. They could potentially decrease the demand for hospital-based imaging devices and software due to the ease of providing diagnoses to the patients.
Market Segmentation
Global Brain Disease Modalities and Software Market (by Product)
The global brain disease modalities and software market has been segmented on the basis of product type into brain modalities (PET devices, PET-CT, PET-MRI, CT devices, and MRI devices) and brain analysis software.
Global Brain Disease Modalities and Software Market (by Indication)
The global brain disease modalities and software market has been segmented on the basis of indication into two major segments, namely, brain diseases (brain and central nervous system cancer, idiopathic epilepsy, ischemic stroke, and other brain diseases) and neurodegenerative diseases (Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, motor neuron disease, and other neurodegenerative diseases). Brain diseases could have several underlying causes spanning illness, injury, or genetic manifestations. To diagnose any brain disorder, the initial steps undertaken include preliminary blood tests and understanding the family's medical background. In addition, an imaging scan is a popular method to detect any abnormalities in brain structure, and tests such as electroencephalogram (EEG) can also be conducted to analyze the underlying electrical activity in the brain.
Global Brain Disease Modalities and Software Market (by Region)
The different regions covered under the global brain disease modalities and software market include North America, Europe, Asia-Pacific, and Rest-of-the-World.
North America and Europe are two of the largest markets for brain disease modalities and software, while developing countries are expected to register strong growth in their adoption in the near future.
Key Market Players and Competition Synopsis
Some of the key players operating in the market include United Imaging Healthcare, Koninklijke Philips N.V., General Electric Company, Canon Inc., Siemens Healthineers AG, Vuno Co., Ltd., Fujifilm Holdings Corporation, Aspect Imaging, IXICO, QMENTA, Cortechs.ai, Quantib, Brainomix, Qure.AI, Imaging Biometrics and A.I., and Analysis, Inc.
In the past few years, the global brain disease modalities and software market has witnessed several strategic and technological developments undertaken by the different market players to attain their respective market shares in this emerging domain. Some of the strategies covered in this segment are funding activities, mergers and acquisitions (M&A), partnerships, alliances, and business expansions, regulatory and legal activities, and new offerings. The preferred strategy for companies has been regulatory and legal activities followed by partnerships and business expansions.*PDF email from publisher allows for 1-3 users, withpermission to print*
Companies Mentioned
United Imaging Healthcare Co., Ltd.
Koninklijke Philips N.V.
General Electric Company
Canon, Inc.
Siemens Healthineers AG
Vuno Co., Ltd.
Fujifilm Holdings Corporation
Aspect Imaging
IXICO
QMENTA
Cortechs.ai
Quantib
Brainomix
Qure.AI
Imaging Biometrics, LLC
A.I. Analysis, Inc.
- 1 Markets
- 1.1 Market Outlook
- 1.1.1 Product Definition
- 1.1.2 Inclusion and Exclusion Criteria
- 1.1.3 Key Findings
- 1.1.4 Market Growth Scenario
- 1.1.4.1 Realistic Growth
- 1.1.4.2 Optimistic Growth
- 1.1.4.3 Pessimistic/Conservative Growth
- 1.2 Industry Outlook
- 1.2.1 Technology Landscape
- 1.2.1.1 Key Trends
- 1.2.1.1.1 Integration of Hardware and Software Solutions for Imaging
- 1.2.1.1.2 Investigation of Ensemble Models that Involve Multiple Classifiers such as Biomarkers and Patient Features
- 1.2.1.1.3 Rising Preference for Portable Brain Scanners and Wearables
- 1.2.1.1.4 Integration of Augmented Reality with Medical Imaging
- 1.2.1.1.5 Increased Focus on Targeting the Pediatric Population
- 1.2.2 Opportunity Assessment
- 1.2.2.1 Short-Term Potential
- 1.2.2.2 Long-Term Potential
- 1.2.3 Product Benchmarking
- 1.2.4 Patent Analysis
- 1.2.4.1 Patent Analysis by Country/Cluster
- 1.2.4.2 Patent Analysis by Year
- 1.3 Impact of COVID-19 on the Global Brain Disease Modalities and Software Market
- 1.3.1 Impact on Facilities
- 1.3.2 Impact on Modalities Adoption
- 1.3.3 Impact on Market Size
- 1.3.3.1 Pre-COVID-19 Phase
- 1.3.3.2 During-COVID-19 Phase
- 1.3.3.3 Post-COVID-19 Phase
- 1.4 Business Dynamics
- 1.4.1 Impact Analysis
- 1.4.2 Business Drivers
- 1.4.2.1 Increasing Prevalence of Neurological Disorders
- 1.4.2.2 Rising AI Integration in the Field of Medical Imaging
- 1.4.2.3 Increasing Demand for Safer and Non-Invasive Devices for Medical Imaging
- 1.4.3 Business Restraints
- 1.4.3.1 High Upfront Cost of Imaging Devices
- 1.4.3.2 Declining Availability of Helium
- 1.4.4 Business Opportunities
- 1.4.4.1 Integration of Imaging Solutions with Novel Biomarkers to Enable Diagnosis of a Wider Range of Neurological Disorders
- 1.4.4.2 Integration of 3D Amplified MRI, a New Technological Advancement
- 2 Application
- 2.1 Brain Disease Modalities and Software Market (by Indication)
- 2.1.1 Opportunity Assessment
- 2.1.2 Growth Share Matrix
- 2.1.3 Brain Diseases
- 2.1.3.1 Patient Volume
- 2.1.3.2 Brain and Central Nervous System Cancer
- 2.1.3.2.1 Market Trend
- 2.1.3.2.2 Market Size and Forecast
- 2.1.3.2.3 Examination Process
- 2.1.3.2.4 Key Modalities Analysis
- 2.1.3.3 Idiopathic Epilepsy
- 2.1.3.3.1 Market Trend
- 2.1.3.3.2 Market Size and Forecast
- 2.1.3.3.3 Examination Process
- 2.1.3.3.4 Key Modalities Analysis
- 2.1.3.4 Ischemic Stroke
- 2.1.3.4.1 Market Trend
- 2.1.3.4.2 Market Size and Forecast
- 2.1.3.4.3 Examination Process
- 2.1.3.4.4 Key Modalities Analysis
- 2.1.3.5 Other Brain Diseases
- 2.1.3.5.1 Market Trend
- 2.1.3.5.2 Market Size and Forecast
- 2.1.3.5.3 Examination Process
- 2.1.3.5.4 Key Modalities Analysis
- 2.1.4 Neurodegenerative Diseases
- 2.1.4.1 Patient Volume
- 2.1.4.2 Key Examination Process for Disease Confirmation
- 2.1.4.3 Alzheimer’s Disease
- 2.1.4.3.1 Market Trend
- 2.1.4.3.2 Market Size and Forecast
- 2.1.4.3.3 Medical Bill and Fee
- 2.1.4.3.3.1 North America
- 2.1.4.3.3.2 Europe
- 2.1.4.3.3.3 Asia-Pacific
- 2.1.4.3.3.4 Rest-of-the-World
- 2.1.4.4 Multiple Sclerosis
- 2.1.4.4.1 Market Trend
- 2.1.4.4.2 Market Size and Forecast
- 2.1.4.4.3 Medical Bill and Fee
- 2.1.4.4.3.1 North America
- 2.1.4.4.3.2 Europe
- 2.1.4.4.3.3 Asia-Pacific
- 2.1.4.4.3.4 Rest-of-the-World
- 2.1.4.5 Parkinson’s Disease
- 2.1.4.5.1 Market Trend
- 2.1.4.5.2 Market Size and Forecast
- 2.1.4.5.3 Medical Bill and Fee
- 2.1.4.5.3.1 North America
- 2.1.4.5.3.2 Europe
- 2.1.4.5.3.3 Asia-Pacific
- 2.1.4.5.3.4 Rest-of-the-World
- 2.1.4.6 Motor Neuron Disease
- 2.1.4.6.1 Market Trend
- 2.1.4.6.2 Market Size and Forecast
- 2.1.4.6.3 Medical Bill and Fee
- 2.1.4.6.3.1 North America
- 2.1.4.6.3.2 Europe
- 2.1.4.6.3.3 Asia-Pacific
- 2.1.4.6.3.4 Rest-of-the-World
- 2.1.4.7 Other Neurodegenerative Diseases
- 2.1.4.7.1 Market Trend
- 2.1.4.7.2 Market Size and Forecast
- 2.1.4.7.3 Medical Bill and Fee
- 2.1.4.7.3.1 North America
- 2.1.4.7.3.2 Europe
- 2.1.4.7.3.3 Asia-Pacific
- 2.1.4.7.3.4 Rest-of-the-World
- 2.2 Global Brain Disease Modalities and Software Market (by Patient Type)
- 2.2.1 Opportunity Assessment
- 2.2.2 Adults
- 2.2.2.1 Market Trends
- 2.2.2.2 Market Size and Forecast
- 2.2.3 Pediatrics and Infants
- 2.2.3.1 Market Trends
- 2.2.3.2 Market Size and Forecast
- 2.3 Global Brain Disease Modalities and Software Market (by End User)
- 2.3.1 Opportunity Assessment
- 2.3.2 Hospitals and Clinics
- 2.3.3 Diagnostic Imaging Centers
- 2.3.4 Ambulatory Surgery Centers
- 3 Products
- 3.1 Brain Disease Modalities and Software Market (by Product)
- 3.1.1 Opportunity Assessment
- 3.1.2 Growth Share Matrix
- 3.1.3 Brain Modalities
- 3.1.3.1 Market Size and Forecast
- 3.1.3.2 by Type
- 3.1.3.2.1 PET Devices
- 3.1.3.2.2 PET-CT
- 3.1.3.2.3 PET-MRI
- 3.1.3.2.4 CT Devices
- 3.1.3.2.5 MRI Devices
- 3.1.4 Brain Analysis Software
- 3.1.4.1 Market Trends
- 3.1.4.1.1 North America
- 3.1.4.1.2 Europe
- 3.1.4.1.3 Asia-Pacific
- 3.1.4.1.4 Rest-of-the-World
- 3.1.4.2 Pricing Analysis
- 3.1.4.3 Vendor Trends
- 3.1.4.3.1 Market Share Analysis
- 3.1.4.3.2 Skills Analysis
- 3.1.4.3.3 Purpose/Application Analysis
- 3.1.4.3.4 Target Disease Analysis
- 3.1.4.3.5 Modality Analysis
- 3.1.4.3.6 Analytical Report Status
- 3.1.4.3.7 Regulatory Status Analysis
- 4 Region
- 4.1 North America Brain Disease Modalities and Software Market
- 4.1.1 Market
- 4.1.1.1 Regulatory Framework
- 4.1.1.2 Opportunity Assessment
- 4.1.1.3 Market Dynamics
- 4.1.1.3.1 Impact Analysis
- 4.1.1.4 Sizing and Forecast Analysis
- 4.1.2 Application
- 4.1.2.1 North America Brain Disease Modalities and Software Market (by Indication)
- 4.1.2.2 North America Brain Disease Modalities and Software Market (by Patient Type)
- 4.1.2.3 North America Brain Disease Modalities and Software Market (by End User)
- 4.1.3 Product
- 4.1.3.1 North America Brain Disease Modalities and Software Market (by Product)
- 4.1.4 North America Brain Disease Modalities and Software Market (by Country)
- 4.1.4.1 U.S.
- 4.1.4.2 Canada
- 4.2 Europe Brain Disease Modalities and Software Market
- 4.2.1 Market
- 4.2.1.1 Regulatory Framework
- 4.2.1.2 Opportunity Assessment
- 4.2.1.3 Market Dynamics
- 4.2.1.3.1 Impact Analysis
- 4.2.1.4 Sizing and Forecast Analysis
- 4.2.2 Application
- 4.2.2.1 Europe Brain Disease Modalities and Software Market (by Indication)
- 4.2.2.2 Europe Brain Disease Modalities and Software Market (by Patient Type)
- 4.2.2.3 Europe Brain Disease Modalities and Software Market (by End User)
- 4.2.3 Product
- 4.2.3.1 Europe Brain Disease Modalities and Software Market (by Product)
- 4.2.4 Europe Brain Disease Modalities and Software Market (by Country)
- 4.2.4.1 Germany
- 4.2.4.2 U.K.
- 4.2.4.3 France
- 4.2.4.4 Italy
- 4.2.4.5 Spain
- 4.2.4.6 Rest-of-Europe
- 4.3 Asia-Pacific Brain Disease Modalities and Software Market
- 4.3.1 Market
- 4.3.1.1 Regulatory Framework
- 4.3.1.2 Opportunity Assessment
- 4.3.1.3 Market Dynamics
- 4.3.1.3.1 Impact Analysis
- 4.3.1.4 Sizing and Forecast Analysis
- 4.3.2 Application
- 4.3.2.1 Asia-Pacific Brain Disease Modalities and Software Market (by Indication)
- 4.3.2.2 Asia-Pacific Brain Disease Modalities and Software Market (by Patient Type)
- 4.3.2.3 Asia-Pacific Brain Disease Modalities and Software Market (by End User)
- 4.3.3 Product
- 4.3.3.1 Asia-Pacific Brain Disease Modalities and Software Market (by Product)
- 4.3.4 Asia-Pacific Brain Disease Modalities and Software Market (by Country)
- 4.3.4.1 Japan
- 4.3.4.2 China
- 4.3.4.3 India
- 4.3.4.4 South Korea
- 4.3.4.5 Australia and New Zealand
- 4.3.4.6 Rest-of-Asia-Pacific
- 4.4 Rest-of-the-World Brain Disease Modalities and Software Market
- 4.4.1 Market
- 4.4.1.1 Regulatory Framework
- 4.4.1.2 Opportunity Assessment
- 4.4.1.3 Market Dynamics
- 4.4.1.3.1 Impact Analysis
- 4.4.1.4 Sizing and Forecast Analysis
- 4.4.2 Application
- 4.4.2.1 Rest-of-the-World Brain Disease Modalities and Software Market (by Indication)
- 4.4.2.2 Rest-of-the-World Brain Disease Modalities and Software Market (by Patient Type)
- 4.4.2.3 Rest-of-the-World Brain Disease Modalities and Software Market (by End User)
- 4.4.3 Product
- 4.4.3.1 Rest-of-the-World Brain Disease Modalities and Software Market (by Product)
- 4.4.4 Rest-of-the-World Brain Disease Modalities and Software Market (by Region)
- 4.4.4.1 Latin America
- 4.4.4.2 Middle East and Africa
- 5 Markets - Competitive Benchmarking & Company Profiles
- 5.1 Competitive Benchmarking and Company Profiles
- 5.1.1 Competitive Landscape
- 5.1.1.1 Key Strategies and Developments
- 5.1.1.1.1 Partnerships, Alliances, and Business Expansions
- 5.1.1.1.2 Funding Activities
- 5.1.1.1.3 New Offerings
- 5.1.1.1.4 Mergers and Acquisitions
- 5.1.1.1.5 Regulatory and Legal Activities
- 5.2 Market Share Analysis
- 5.3 Company Profiles
- 5.3.1 Brain Disease Modalities and Software Companies
- 5.3.1.1 United Imaging Healthcare Co., Ltd.
- 5.3.1.1.1 Company Overview
- 5.3.1.1.2 Role of United Imaging Healthcare Co., Ltd. in the Global Brain Disease Modalities and Software Market
- 5.3.1.1.3 Product Portfolio and Offerings
- 5.3.1.1.4 Recent Developments
- 5.3.1.1.5 SWOT Analysis
- 5.3.1.2 Koninklijke Philips N.V.
- 5.3.1.2.1 Company Overview
- 5.3.1.2.2 Role of Koninklijke Philips N.V. in the Global Brain Disease Modalities and Software Market
- 5.3.1.2.3 Product Portfolio and Offerings
- 5.3.1.2.4 Financials
- 5.3.1.2.5 SWOT Analysis
- 5.3.1.3 General Electric Company
- 5.3.1.3.1 Company Overview
- 5.3.1.3.2 Role of General Electric Company in the Global Brain Disease Modalities and Software Market
- 5.3.1.3.3 Product Portfolio and Offerings
- 5.3.1.3.4 Financials
- 5.3.1.3.5 SWOT Analysis
- 5.3.1.4 Canon, Inc.
- 5.3.1.4.1 Company Overview
- 5.3.1.4.2 Role of Canon, Inc. in the Global Brain Disease Modalities and Software Market
- 5.3.1.4.3 Product Portfolio and Offerings
- 5.3.1.4.4 Recent Developments
- 5.3.1.4.5 Financials
- 5.3.1.4.6 SWOT Analysis
- 5.3.1.5 Siemens Healthineers AG
- 5.3.1.5.1 Company Overview
- 5.3.1.5.2 Role of Siemens Healthineers AG in the Global Brain Disease Modalities and Software Market
- 5.3.1.5.3 Product Portfolio and Offerings
- 5.3.1.5.4 Financials
- 5.3.1.5.5 Recent Developments
- 5.3.1.5.6 SWOT Analysis
- 5.3.1.6 Vuno Co., Ltd.
- 5.3.1.6.1 Company Overview
- 5.3.1.6.2 Role of Vuno Co., Ltd. in the Global Brain Disease Modalities and Software Market
- 5.3.1.6.3 Product Portfolio and Offerings
- 5.3.1.6.4 Recent Developments
- 5.3.1.6.5 SWOT Analysis
- 5.3.1.7 Fujifilm Holdings Corporation
- 5.3.1.7.1 Company Overview
- 5.3.1.7.2 Role of Fujifilm Holdings Corporation in the Global Brain Disease Modalities and Software Market
- 5.3.1.7.3 Product Portfolio
- 5.3.1.7.4 Financials
- 5.3.1.7.5 Recent Developments
- 5.3.1.7.6 SWOT Analysis
- 5.3.1.8 Aspect Imaging
- 5.3.1.8.1 Company Overview
- 5.3.1.8.2 Role of Aspect Imaging in the Global Brain Disease Modalities and Software Market
- 5.3.1.8.3 Product Portfolio and Offerings
- 5.3.1.8.4 SWOT Analysis
- 5.3.2 Brain Imaging Software Companies
- 5.3.2.1 IXICO
- 5.3.2.1.1 Company Overview
- 5.3.2.1.2 Role of IXICO in the Global Brain Disease Modalities and Software Market
- 5.3.2.1.3 Product Portfolio and Offerings
- 5.3.2.1.4 Financials
- 5.3.2.1.5 Recent Developments
- 5.3.2.1.6 SWOT Analysis
- 5.3.2.2 QMENTA
- 5.3.2.2.1 Company Overview
- 5.3.2.2.2 Role of QMENTA in the Global Brain Disease Modalities and Software Market
- 5.3.2.2.3 Product Portfolio and Offerings
- 5.3.2.2.4 SWOT Analysis
- 5.3.2.3 Cortechs.ai
- 5.3.2.3.1 Company Overview
- 5.3.2.3.2 Role of Cortechs.ai in the Global Brain Disease Modalities and Software Market
- 5.3.2.3.3 Product Portfolio and Offerings
- 5.3.2.3.4 Recent Developments
- 5.3.2.3.5 SWOT Analysis
- 5.3.2.4 Quantib
- 5.3.2.4.1 Company Overview
- 5.3.2.4.2 Role of Quantib in the Global Brain Disease Modalities and Software Market
- 5.3.2.4.3 Product Portfolio and Offerings
- 5.3.2.4.4 Recent Developments
- 5.3.2.4.5 SWOT Analysis
- 5.3.2.5 Brainomix
- 5.3.2.5.1 Company Overview
- 5.3.2.5.2 Role of Brainomix in the Global Brain Disease Modalities and Software Market
- 5.3.2.5.3 Product Portfolio and Offerings
- 5.3.2.5.4 Recent Developments
- 5.3.2.5.5 SWOT Analysis
- 5.3.2.6 Qure.AI
- 5.3.2.6.1 Company Overview
- 5.3.2.6.2 Role of Qure.AI in the Global Brain Disease Modalities and Software Market
- 5.3.2.6.3 Product Portfolio and Offerings
- 5.3.2.6.4 Recent Developments
- 5.3.2.6.5 SWOT Analysis
- 5.3.2.7 Imaging Biometrics, LLC
- 5.3.2.7.1 Company Overview
- 5.3.2.7.2 Role of Imaging Biometrics, LLC in the Global Brain Disease Modalities and Software Market
- 5.3.2.7.3 Product Portfolio and Offerings
- 5.3.2.7.4 Recent Developments
- 5.3.2.7.5 SWOT Analysis
- 5.3.2.8 A.I. Analysis, Inc.
- 5.3.2.8.1 Company Overview
- 5.3.2.8.2 Role of A.I. Analysis, Inc. in the Global Brain Disease Modalities and Software Market
- 5.3.2.8.3 Product Portfolio and Offerings
- 5.3.2.8.4 SWOT Analysis
- 6 Research Methodology
- 6.1 Data Collection and Analysis
- 6.2 Data Sources
- 6.2.1 Primary Data Sources
- 6.2.2 Secondary Data Sources
- 6.3 Data Triangulation
- 6.4 Market Estimation
- 6.5 Forecast Period Selection Criteria
- 6.6 Assumptions and Limitations
- List of Figures
- Figure 1: Global Brain Disease Modalities and Software Market, Impact Analysis
- Figure 2: Market Size Forecast (by Region), 2021 and 2031
- Figure 3: Global Brain Disease Modalities and Software Market, Overall Coverage
- Figure 4: Global Brain Disease Modalities and Software Market, Potential Forecast Scenarios
- Figure 5: Global Brain Disease Modalities and Software Market Size and Growth Potential (Realistic Scenario), $Million, 2020-2031
- Figure 6: Global Brain Disease Modalities and Software Market Size and Growth Potential (Optimistic Scenario), $Million, 2020-2031
- Figure 7: Global Brain Disease Modalities and Software Market Size and Growth Potential (Pessimistic Scenario/Conservative Growth), $Million, 2020-2031
- Figure 8: Global Brain Disease Modalities and Software Market, Key Technology Trends
- Figure 9: Global Brain Disease Modalities and Software Market Key Trends, Short-Term Potential
- Figure 10: Global Brain Disease Modalities and Software Market Key Trends, Long-Term Potential
- Figure 11: Global Brain Disease Modalities and Software Market Patent Analysis (by Country/Cluster), 2018-2021
- Figure 12: Global Brain Disease Modalities and Software Market Patent Analysis (by Year), 2018-2021
- Figure 13: Global Brain Disease Modalities and Software Market, Pre-COVID-19 Phase, $Million, 2018-2031
- Figure 14: Global Brain Disease Modalities and Software Market, Impact Analysis
- Figure 15: Global Brain Disease Modalities and Software Market, Prevalence of Brain Diseases, 2010, 2015, and 2019
- Figure 16: Global Brain Disease Modalities and Software Market, Prevalence of Neurodegenerative Diseases, 2010, 2015, and 2019
- Figure 17: Global Brain Disease Modalities and Software Market, Role of AI in Medical Imaging
- Figure 18: Global Brain Disease Modalities and Software Market (by Indication)
- Figure 19: Global Brain Disease Modalities and Software Market Incremental Opportunity (by Indication), $Million, 2021-2031
- Figure 20: Global Brain Disease Modalities and Software Market, Growth Share Matrix (by Indication), 2021-2031
- Figure 21: Global Brain Disease Modalities and Software Market (Brain and Central Nervous System Cancer), $Million, 2020-2031
- Figure 22: Global Brain Disease Modalities and Software Market (Idiopathic Epilepsy), $Million, 2020-2031
- Figure 23: Global Brain Disease Modalities and Software Market (Ischemic Stroke), $Million, 2020-2031
- Figure 24: Global Brain Disease Modalities and Software Market (Other Brain Diseases), $Million, 2020-2031
- Figure 25: Global Brain Disease Modalities and Software Market (Alzheimer’s Disease), $Million, 2020-2031
- Figure 26: Global Brain Disease Modalities and Software Market (Multiple Sclerosis), $Million, 2020-2031
- Figure 27: Global Brain Disease Modalities and Software Market (Parkinson’s Disease), $Million, 2020-2031
- Figure 28: Global Brain Disease Modalities and Software Market (Motor Neuron Disease), $Million, 2020-2031
- Figure 29: Global Brain Disease Modalities and Software Market (Other Neurodegenerative Diseases), $Million, 2020-2031
- Figure 30: Global Brain Disease Modalities and Software Market (by Patient Type)
- Figure 31: Global Brain Disease Modalities and Software Market Incremental Opportunity (by Patient Type), $Million, 2021-2031
- Figure 32: Global Brain Disease Modalities and Software Market (Adults), $Million, 2020-2031
- Figure 33: Global Brain Disease Modalities and Software Market (Pediatrics and Infants), $Million, 2020-2031
- Figure 34: Global Brain Disease Modalities and Software Market (by End User)
- Figure 35: Global Brain Disease Modalities and Software Market, Incremental Opportunity (by End User), $Million, 2021-2031
- Figure 36: Global Brain Disease Modalities and Software Market (Hospitals and Clinics), $Million, 2020-2031
- Figure 37: Global Brain Disease Modalities and Software Market (Diagnostic Imaging Centers), $Million, 2020-2031
- Figure 38: Global Brain Disease Modalities and Software Market (Ambulatory Surgery Centers), $Million, 2020-2031
- Figure 39: Global Brain Disease Modalities and Software Market (by Product)
- Figure 40: Global Brain Disease Modalities and Software Market, Incremental Opportunity (by Product), $Million, 2021-2031
- Figure 41: Global Brain Disease Modalities and Software Market, Growth Share Matrix (by Product), 2021-2031
- Figure 42: Global Brain Disease Modalities and Software Market (by Brain Modalities), $Million, 2020-2031
- Figure 43: North America Brain Disease Modalities and Software Market, PET Devices, $Million, 2020-2031
- Figure 44: North America Brain Disease Modalities and Software Market, PET-CT, $Million, 2020-2031
- Figure 45: North America Brain Disease Modalities and Software Market, PET-MRI, $Million, 2020-2031
- Figure 46: North America Brain Disease Modalities and Software Market, CT Devices, $Million, 2020-2031
- Figure 47: North America Brain Disease Modalities and Software Market, MRI Devices, $Million, 2020-2031
- Figure 48: North America Brain Disease Modalities and Software Market, Brain Analysis Software, $Million, 2020-2031
- Figure 49: Global Brain Analysis Software Market, Company Revenue Share Analysis, $Million, 2021
- Figure 50: Global Brain Disease Modalities and Software Market (by Region), $Million, 2020-2031
- Figure 51: North America Brain Disease Modalities and Software Market, Incremental Revenue Opportunity (by Country), $Million, 2021-2031
- Figure 52: North America Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 53: North America Brain Disease Modalities and Software Market (by Indication), $Million, 2020-2031
- Figure 54: North America Brain Disease Modalities and Software Market (by Brain Diseases), $Million, 2020-2031
- Figure 55: North America Brain Disease Modalities and Software Market (by Neurodegenerative Diseases), $Million, 2020-2031
- Figure 56: North America Brain Disease Modalities and Software Market (by Patient Type), $Million, 2020-2031
- Figure 57: North America Brain Disease Modalities and Software Market (by End User), $Million, 2020-2031
- Figure 58: North America Brain Disease Modalities and Software Market (by Product), $Million, 2020-2031
- Figure 59: North America Brain Disease Modalities and Software Market (by Country), $Million, 2021 and 2031
- Figure 60: U.S. Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 61: Canada Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 62: Europe Brain Disease Modalities and Software Market Incremental Revenue Opportunity (by Country), $Million, 2021-2031
- Figure 63: Europe Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 64: Europe Brain Disease Modalities and Software Market (by Indication), $Million, 2020-2031
- Figure 65: Europe Brain Disease Modalities and Software Market (by Brain Diseases), $Million, 2020-2031
- Figure 66: Europe Brain Disease Modalities and Software Market (by Neurodegenerative Diseases), $Million, 2020-2031
- Figure 67: Europe Brain Disease Modalities and Software Market (by Patient Type), $Million, 2020-2031
- Figure 68: Europe Brain Disease Modalities and Software Market (by End User), $Million, 2020-2031
- Figure 69: Europe Brain Disease Modalities and Software Market (by Product), $Million, 2020-2031
- Figure 70: Europe Brain Disease Modalities and Software Market (by Country), $Million, 2021 and 2031
- Figure 71: Germany Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 72: U.K. Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 73: France Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 74: Italy Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 75: Spain Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 76: Rest-of-Europe Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 77: Asia-Pacific Brain Disease Modalities and Software Market, Incremental Revenue Opportunity (by Country), $Million, 2021-2031
- Figure 78: Asia-Pacific Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 79: Asia-Pacific Brain Disease Modalities and Software Market (by Indication), $Million, 2020-2031
- Figure 80: Asia-Pacific Brain Disease Modalities and Software Market (by Brain Diseases), $Million, 2020-2031
- Figure 81: Asia-Pacific Brain Disease Modalities and Software Market (by Neurodegenerative Diseases), $Million, 2020-2031
- Figure 82: Asia-Pacific Brain Disease Modalities and Software Market (by Patient Type), $Million, 2020-2031
- Figure 83: Asia-Pacific Brain Disease Modalities and Software Market (by End User), $Million, 2020-2031
- Figure 84: Asia-Pacific Brain Disease Modalities and Software Market (by Product), $Million, 2020-2031
- Figure 85: Asia-Pacific Brain Disease Modalities and Software Market (by Country), $Million, 2021 and 2031
- Figure 86: Japan Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 87: China Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 88: India Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 89: South Korea Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 90: Australia and New Zealand Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 91: Rest-of-Asia-Pacific Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 92: Rest-of-the-World Brain Disease Modalities and Software Market Incremental Revenue Opportunity (by Country), $Million, 2021-2031
- Figure 93: Rest-of-the-World Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 94: Rest-of-the-World Brain Disease Modalities and Software Market (by Indication), $Million, 2020-2031
- Figure 95: Rest-of-the-World Brain Disease Modalities and Software Market (by Brain Diseases), $Million, 2020-2031
- Figure 96: Rest-of-the-World Brain Disease Modalities and Software Market (by Neurodegenerative Diseases), $Million, 2020-2031
- Figure 97: Rest-of-the-World Brain Disease Modalities and Software Market (by Patient Type), $Million, 2020-2031
- Figure 98: Rest-of-the-World Brain Disease Modalities and Software Market (by End User), $Million, 2020-2031
- Figure 99: Rest-of-the-World Brain Disease Modalities and Software Market (by Product), $Million, 2020-2031
- Figure 100: Rest-of-the-World Brain Disease Modalities and Software Market (by Region), $Million, 2021 and 2031
- Figure 101: Latin America Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 102: Middle East and Africa Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 103: Partnerships, Alliances, and Business Expansions (by Company), January 2018-December 2021
- Figure 104: Funding Activities (by Company), January 2018-December 2021
- Figure 105: New Offerings (by Company), January 2018-December 2021
- Figure 106: Mergers and Acquisitions (by Company), January 2018-December 2021
- Figure 107: Mergers and Acquisitions (by Company), January 2018-December 2021
- Figure 108: Global Brain Disease Modalities and Software Market, Company Revenue Share Analysis, $Million, 2021
- Figure 109: United Imaging Healthcare Co., Ltd.: Overall Product Portfolio
- Figure 110: Koninklijke Philips N.V.: Overall Product Portfolio
- Figure 111: Koninklijke Philips N.V.: Overall Financials, $Million, 2018-2020
- Figure 112: Koninklijke Philips N.V.: Net Revenue (by Segment), $Million, 2018-2020
- Figure 113: Koninklijke Philips N.V.: Net Revenue (by Region), $Million, 2018-2020
- Figure 114: Koninklijke Philips N.V.: R&D Expenditure, $Million, 2018-2020
- Figure 115: General Electric Company: Overall Product Portfolio
- Figure 116: General Electric Company: Overall Financials, $Million, 2018-2020
- Figure 117: General Electric Company: Net Revenue (by Segment), $Million, 2018-2020
- Figure 118: General Electric Company: Net Revenue (by Region), $Million, 2018-2020
- Figure 119: General Electric Company: R&D Expenditure, $Million, 2018-2020
- Figure 120: Canon, Inc.: Overall Product Portfolio
- Figure 121: Canon, Inc.: Overall Financials, $Million, 2018-2020
- Figure 122: Canon, Inc.: Net Revenue (by Segment), $Million, 2018-2020
- Figure 123: Canon, Inc.: Revenue (by Region), $Million, 2018-2020
- Figure 124: Canon, Inc.: R&D Expenditure, $Million, 2018-2020
- Figure 125: Siemens Healthineers AG: Overall Product Portfolio
- Figure 126: Siemens Healthineers AG: Overall Financials, $Million, 2019-2021
- Figure 127: Siemens Healthineers AG: Net Revenue (by Segment), $Million, 2019-2021
- Figure 128: Siemens Healthineers AG: Net Revenue (by Region), $Million, 2019-2021
- Figure 129: Siemens Healthineers AG: R&D Expenditure, $Million, 2019-2021
- Figure 130: Vuno Co., Ltd.: Product Portfolio
- Figure 131: Fujifilm Holdings Corporation: Product Portfolio
- Figure 132: Fujifilm Holdings Corporation: Overall Financials, $Million, 2018-2020
- Figure 133: Fujifilm Holdings Corporation: Net Revenue (by Segment), $Million, 2018-2020
- Figure 134: Fujifilm Holdings Corporation: Net Revenue (by Region), $Million, 2018-2020
- Figure 135: Fujifilm Holdings Corporation: R&D Expenditure, $Million, 2018-2020
- Figure 136: Aspect Imaging: Product Offerings
- Figure 137: IXICO: Product Portfolio
- Figure 138: IXICO: Overall Financials, $Million, 2019-2021
- Figure 139: IXICO (by Region), $Million, 2020-2021
- Figure 140: IXICO: R&D Expenditure, $Million, 2019-2021
- Figure 141: QMENTA: Product Portfolio
- Figure 142: Cortechs.ai: Product Portfolio
- Figure 143: Quantib: Product Portfolio
- Figure 144: Brainomix: Product Portfolio
- Figure 145: Qure.AI: Product Portfolio
- Figure 146: Imaging Biometrics, LLC: Product Portfolio
- Figure 147: A.I. Analysis, Inc.: Product Portfolio
- Figure 148: Global Brain Disease Modalities and Software Market: Research Methodology
- Figure 149: Primary Research
- Figure 150: Secondary Research
- Figure 151: Data Triangulation
- Figure 152: Global Brain Disease Modalities and Software Market Research Process
- Figure 153: Assumptions and Limitations
- List of Tables
- Table 1: Key Challenges and Possible Solutions for Players in the Global Brain Disease Modalities and Software Market
- Table 2: Global Brain Disease Modalities and Software Market, Quarterly Key Developments Analysis, January 2018-December 2021
- Table 3: Global Brain Disease Modalities and Software Market, Product Offerings, by Modality Types and Software
- Table 4: Global Brain Disease Modalities and Software Market, Strength of Product Offerings, by Modality Types and Software
- Table 5: Global Brain Disease Modalities and Software Market, Patient Volume of Brain Diseases
- Table 6: Global Brain Disease Modalities and Software Market, Key Modalities Analysis for Brain and Central Nervous System Cancer
- Table 7: Global Brain Disease Modalities and Software Market, Key Modalities Analysis for Idiopathic Epilepsy
- Table 8: Global Brain Disease Modalities and Software Market, Key Modalities Analysis for Ischemic Stroke
- Table 9: Global Brain Disease Modalities and Software Market, Key Modalities Analysis for Other Brain Diseases
- Table 10: Global Brain Disease Modalities and Software Market, Patient Volume of Neurodegenerative Diseases
- Table 11: Global Brain Disease Modalities and Software Market, Imaging Fee, North America
- Table 12: Global Brain Disease Modalities and Software Market, Imaging Fee, Europe
- Table 13: Global Brain Disease Modalities and Software Market, Imaging Fee, Asia-Pacific
- Table 14: Global Brain Disease Modalities and Software Market, Imaging Fee, Rest-of-the-World
- Table 15: Global Brain Disease Modalities and Software Market, Imaging Fee, North America
- Table 16: Global Brain Disease Modalities and Software Market, Imaging Fee, Europe
- Table 17: Global Brain Disease Modalities and Software Market, Imaging Fee, Asia-Pacific
- Table 18: Global Brain Disease Modalities and Software Market, Imaging Fee, Rest-of-the-World
- Table 19: Global Brain Disease Modalities and Software Market, Imaging Fee, North America
- Table 20: Global Brain Disease Modalities and Software Market, Imaging Fee, Europe
- Table 21: Global Brain Disease Modalities and Software Market, Imaging Fee, Asia-Pacific
- Table 22: Global Brain Disease Moda
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook